Pulmonary Disease Doctors in Salem, MA - Medicare Status, Address, Contact

2 Pulmonary Disease doctors found. Showing 1 - 2

Daniel Carroll Hagan, DO
Internal Medicine - Pulmonary Disease
Medicare: Not Enrolled in Medicare
Practice Location: 55 Highland Ave, Suite 104, Salem, MA 01970
Phone: 978-745-4489 Fax: 978-354-2085

Dr. Christopher Wesley Humphreys, MD
Internal Medicine - Pulmonary Disease
Medicare: Accepting Medicare Assignments
Practice Location: 55 Highland Ave, Suite 104 (north Shore Pulmonary Associates), Salem, MA 01970
Phone: 978-745-4489 Fax: 978-741-3131

News Archive

Congress facing deadline on Medicare payments to doctors

Preventing the cut in Medicare payments to doctors is estimated to cost more than $20 billion next year. It is considered a near certainty that Congress will address it because of the clout that Medicare and doctors have with lawmakers. Within minutes of Monday's announcement that the supercommittee had failed, the American Medical Association was warning that the 27 percent cut would "force many physicians to limit the number of Medicare and TRICARE patients they can care for in their practices."

International nonproprietary name "auriclosene" approved by WHO for NovaBay's NVC-422

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with first-in-class compounds such as its proprietary Aganocides®, today announced that the World Health Organization (WHO) has approved the international nonproprietary name (INN) "auriclosene" (pronounced awr-rih-CLO-zeen) for the Company's lead Aganocide® compound NVC-422.

NEC, SomaLogic sign agreement to explore aptamer related businesses in life sciences, healthcare markets

NEC Corporation and privately held SomaLogic, Inc. announced today that they have signed an agreement to explore aptamer related businesses in the life sciences and healthcare markets. In addition, NEC announced that it has made an equity investment in SomaLogic in support of a long-term strategic relationship between the two companies.

Nintedanib drug to treat NSCLC is submitted for approval from European Medicines Agency

Boehringer Ingelheim announced the submission of a Marketing Authorisation Application to the European Medicines Agency for the approval of its oral triple angiokinase inhibitor nintedanib, in combination with docetaxel, for the treatment of patients with locally advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first line chemotherapy.

New approach for developing personalized gene therapies to treat retinitis pigmentosa

Columbia University Medical Center researchers have created a way to develop personalized gene therapies for patients with retinitis pigmentosa (RP), a leading cause of vision loss.

Pulmonary Disease Doctors in Salem, MA Accepting Medicare